Comparing belumosudil liquid vs. tablet in healthy men
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests two forms of the drug belumosudil (a liquid and a tablet) to see if they work the same in the body. It's for healthy men and will help decide which version may be easier for patients to take.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man between 18 and 45 years old.
- You are in good health with no major medical conditions.
- You weigh between 110 and 254 pounds, with a body mass index (BMI) between 18 and 32.
- You agree to use contraception if sexually active.
- You do not smoke regularly or take any medications or herbal supplements.
- You have not donated blood in the past 2 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called belumosudil to see how safe it is for people with chronic graft-versus-host disease (cGVHD). If you have had a stem cell transplant and still need treatment for cGVHD after trying other therapies, this trial may be an option.
This trial tests a pill called belumosudil to see if it can help people with chronic graft-versus-host disease (a common complication after a stem cell transplant where donor cells attack your body). It is for patients who have symptoms but are not yet on strong immune-suppressing drugs.
This trial tests whether crushing belumosudil tablets changes how the drug works in people with chronic graft-versus-host-disease (GVHD), a complication after a stem cell transplant. It helps doctors know if taking crushed pills is as effective as whole tablets.
This study tests a new medicine called belumosudil for children with chronic graft-versus-host disease (GVHD) that hasn't improved with at least 2 other treatments. The goal is to see if it can help control the disease and improve symptoms.
This study tests a new medicine called belumosudil for chronic graft-versus-host disease (cGVHD), a condition where donor cells attack the body after a stem cell transplant. The trial compares belumosudil to the best available standard treatments to see if it works better at controlling the condition.
This Phase 2 study tests belumosudil to treat or prevent bronchiolitis obliterans (BOS), a lung complication that can happen after a stem cell transplant. If you qualify, you would be checked closely with breathing tests and scans, and watched for safety and whether lung function improves or stays stable.
Hear when a new Chronic Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.